Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer

被引：0
|
作者：
A. Matrone
A. Prete
A. Nervo
A. Ragni
L. Agate
E. Molinaro
C. Giani
L. Valerio
E. Minaldi
A. Piovesan
R. Elisei
机构：
[1] Pisa University Hospital,Department of Clinical and Experimental Medicine, Unit of Endocrinology
[2] Azienda Ospedaliero Universitaria Città Della Salute E Della Scienza Di Torino,Department of Oncology, Oncological Endocrinology Unit
来源：
Journal of Endocrinological Investigation | 2021年 / 44卷
关键词：
Lenvatinib; Medullary thyroid cancer; Calcitonin; Carcinoembrionic antigen; Tyrosine kinase inhibitors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2139 / 2151
页数：12
相关论文
共 50 条
  • [21] Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review
    Zohreh Maghsoomi
    Zahra Emami
    Ramin Malboosbaf
    Mojtaba Malek
    Mohammad E. Khamseh
    BMC Cancer, 21
  • [22] Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review
    Maghsoomi, Zohreh
    Emami, Zahra
    Malboosbaf, Ramin
    Malek, Mojtaba
    Khamseh, Mohammad E.
    BMC CANCER, 2021, 21 (01)
  • [23] Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
    Degrauwe, Nils
    Sosa, Julie Ann
    Roman, Sanziana
    Deshpande, Hari A.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6
  • [24] Medical Management of Metastatic Medullary Thyroid Cancer
    Maxwell, Jessica E.
    Sherman, Scott K.
    O'Dorisio, Thomas M.
    Howe, James R.
    CANCER, 2014, 120 (21) : 3287 - 3301
  • [25] Biomarker testing in patients diagnosed with advanced/metastatic medullary thyroid cancer in the United States
    Bhandari, Naleen Raj
    Hess, Lisa M.
    Parikh, Rohan C.
    Sireci, Anthony N.
    Krein, Peter M.
    Kaye, James A.
    PERSONALIZED MEDICINE, 2023, 20 (02) : 131 - 142
  • [26] Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
    Robinson, Bruce G.
    Paz-Ares, Luis
    Krebs, Annetta
    Vasselli, James
    Haddad, Robert
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (06): : 2664 - 2671
  • [27] Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma
    Bedrose, Sara
    Miller, Kevin Charles
    Altameemi, Lina
    Ali, Mohamed S.
    Nassar, Sameh
    Garg, Naveen
    Daher, Marilyne
    Eaton, Keith D.
    Yorio, Jeffrey Thomas
    Daniel, Davey B.
    Campbell, Matthew
    Bible, Keith C.
    Ryder, Mabel
    Chintakuntlawar, Ashish, V
    Habra, Mouhammed Amir
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [28] Decreasing utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer
    Maniakas, Anastasios
    Sullivan, Andrew
    Hu, Mimi I.
    Busaidy, Naifa L.
    Cabanillas, Maria E.
    Dadu, Ramona
    Waguespack, Steven G.
    Fisher, Sarah B.
    Graham, Paul H.
    Gross, Neil D.
    Grubbs, Elizabeth G.
    Perrier, Nancy D.
    Wang, Jennifer R.
    Gunn, Brandon
    Garden, Adam S.
    Megahed, Romy
    Navuluri, Sriram
    Li, Xu
    Williams, Michelle D.
    Zafereo, Mark
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2024, 46 (02): : 328 - 335
  • [29] Medullary thyroid cancer: Monitoring and therapy
    Ball, Douglas W.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2007, 36 (03) : 823 - +
  • [30] VANDETANIB THERAPY IN MEDULLARY THYROID CANCER
    Grabowski, P.
    Briest, F.
    Baum, R. P.
    Zaknun, J. J.
    Kulkarni, H. R.
    Zeitz, M.
    Hoersch, D.
    DRUGS OF TODAY, 2012, 48 (11) : 723 - 733
12345